相互作用
Aprepitant + Pexidartinib
重症度: 重大
Aprepitant and Pexidartinib: major interaction.
最終更新日
医療従事者向け・参照専用。このページは簡潔な要約であり、医学的助言ではなく、公式の添付文書や臨床判断に代わるものではありません。処方・調剤の前に必ず確認してください。
このページの臨床コンテンツは英語でのみ提供されています。
概要
Pexidartinib is metabolized by CYP3A4, and aprepitant can increase its exposure. This raises the risk of pexidartinib toxicities, notably hepatotoxicity.
この相互作用をわかりやすく説明すると
Aprepitant and Pexidartinib can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.
Aprepitant belongs to Gastrointestinal Tract; Pexidartinib belongs to Oncology.
なぜ起こるのか
Aprepitant inhibits CYP3A4 metabolism of pexidartinib.
対処法
Avoid if possible; if needed, reduce the pexidartinib dose per labeling and monitor liver tests closely. Return to the previous dose after the inhibitor is stopped for about three half-lives.
薬剤師に尋ねること
- Does the benefit of taking both outweigh the risk in my case?
- Do I need any blood test, ECG or other check while on both?
- What early warning signs should I watch for, and what should I do if they appear?
Pro+会員向け
ページ全体を見る
アカウントを作成してPro+トライアルを始めると、AprepitantとPexidartinibの臨床対応の詳細なアドバイス、追加の注記、エビデンスの詳細、処方全体を対象とした相互作用チェッカーを利用できます。
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
WebでPro+を14日間無料でお試し。カード登録不要。
Aprepitantのその他の相互作用
Pexidartinibのその他の相互作用
よくある質問
Can I take Aprepitant with Pexidartinib?
MediHelp rates the interaction as major. Aprepitant and Pexidartinib can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Pexidartinib is metabolized by CYP3A4, and aprepitant can increase its exposure. This raises the risk of pexidartinib toxicities, notably hepatotoxicity.
How serious is the interaction between Aprepitant and Pexidartinib?
MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid if possible; if needed, reduce the pexidartinib dose per labeling and monitor liver tests closely. Return to the previous dose after the inhibitor is stopped for about three half-lives.
What other medicines interact with Aprepitant?
MediHelp also lists interactions of Aprepitant with, for example, Lomitapide, Pimozide, Avapritinib. The full list is on the Aprepitant page.
完全なモノグラフ、用量、相互作用チェッカーはMediHelpアプリで
MediHelpアプリで、完全なリファレンスを開き、複数薬剤の相互作用をチェックし、用量ツールを利用できます。
